Theolytics secures grant from Innovate UK for Phase I trial of ovarian cancer drug

Theolytics received a £2m grant from Innovate UK to fund a Phase I trial of THEO-260 for platinum-resistant ovarian cancer, aiming to assess safety, tolerability, and optimal dosage.